Abstract:
The oral control drug delivery is the most acceptable delivery system for patient acceptance, industrial
application and economical but still it has several challenges to design a dosage form. The gastro intestinal pHis one of
the major limitations for constant drug release due to different pH variations different regions (stomach vs small
intestine) throughout the GIT. The aim of the present research work was to develop a pH independent oral control release
drug delivery of pH dependent Ondansetron HCl for the treatment of CINV or PONV. The major limitation of the drug
was found burst release in SGF pH 1.2 and highly precipitation in intestinal pH (pH 6.8 phosphate buffer). The
formulator is challenging to develop constant controlled drug release in entire gastro intestinal tract. The techniques
involve the use of pH modulating agents and acidifying agents to achieve pH independent controlled drug release. It was
found that incorporation of anionic polymer (Eudragit L100-55) with control release nonionic HPMC matrix shows pH
independent drug release in both SGF pH 1.2 and pH 6.8 phosphate buffer. In conclusion it was understood that the
release profile of HPMC sellable matrices of Ondansetron HCl with manipulating the micro environmental pH, at
variable pH conditions provided a efficient and predictable results.
